Joincare Pharmaceutical Group Industry (600380.SH): JP-1366 tablets have obtained the Drug Clinical Trial Approval Notice.
Health (600380.SH) announced that recently, its holding subsidiary Lijun Pharmaceutical Group Co., Ltd. (referred to as Lijun Group) has received the "Drug Clinical Trial Approval Notice" (Notification No.: 2026LP01115) issued by the National Medical Products Administration, approving the company's application for JP-1366 tablets to conduct clinical trials for the indication of "eradication of Helicobacter pylori with appropriate antibiotics".
Joincare Pharmaceutical Group Industry (600380.SH) issued an announcement that its holding subsidiary Livzon Pharmaceutical Group Inc. has received the "Drug Clinical Trial Approval Notice" (Notice Number: 2026LP01115) approved and issued by the National Medical Products Administration. The notice approves the company's application to conduct clinical trials of JP-1366 tablets for the indication of "eradication of Helicobacter pylori in combination with appropriate antibiotics."
JP-1366 tablets are an innovative potassium-competitive acid blocker (P-CAB). The indication for this clinical trial application is the eradication of Helicobacter pylori in combination with appropriate antibiotics.
Related Articles
BOSS ZHIPIN-W (02076) spent approximately $4.79 million on April 9 to repurchase approximately 724,800 shares.
CITIC (00267): SkySea Airlines has received a government subsidy of 36.44 million yuan.
Trustee SCHOLAR EDU (01769): purchased 198,000 shares under the stock incentive plan.
BOSS ZHIPIN-W (02076) spent approximately $4.79 million on April 9 to repurchase approximately 724,800 shares.
CITIC (00267): SkySea Airlines has received a government subsidy of 36.44 million yuan.
Trustee SCHOLAR EDU (01769): purchased 198,000 shares under the stock incentive plan.
RECOMMEND
